These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12415707)

  • 1. Matrix metalloproteinase expression in lung cancer.
    Lim M; Jablons DM
    Methods Mol Med; 2003; 74():349-56. PubMed ID: 12415707
    [No Abstract]   [Full Text] [Related]  

  • 2. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer.
    Bonomi P
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):78-86. PubMed ID: 11894017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current usage of molecular targeting drugs].
    Sugio K
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1459-62. PubMed ID: 20860096
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutrophil elastase as a target in lung cancer.
    Moroy G; Alix AJ; Sapi J; Hornebeck W; Bourguet E
    Anticancer Agents Med Chem; 2012 Jul; 12(6):565-79. PubMed ID: 22263788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.
    Van Zandwijk N; Baas P
    Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted biological treatments in NSCLC. Farnesyl transferase inhibitors.
    Marangolo M
    Suppl Tumori; 2002; 1(4):S49. PubMed ID: 12415819
    [No Abstract]   [Full Text] [Related]  

  • 7. Histone deacetylase inhibitors in non-small-cell lung cancer.
    Witta S
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S404-6. PubMed ID: 23160335
    [No Abstract]   [Full Text] [Related]  

  • 8. Crizotinib (xalkori) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
    [No Abstract]   [Full Text] [Related]  

  • 9. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.
    Chetty C; Rao JS; Lakka SS
    Pharmacogenomics; 2011 Apr; 12(4):535-46. PubMed ID: 21521025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
    Adjei AA
    Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRC inhibitors.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S466-7. PubMed ID: 21102241
    [No Abstract]   [Full Text] [Related]  

  • 12. Up-regulation of matrix metalloproteinase family gene involvement in ursolic acid-induced human lung non-small carcinoma cell apoptosis.
    Lai MY; Leung HW; Yang WH; Chen WH; Lee HZ
    Anticancer Res; 2007; 27(1A):145-53. PubMed ID: 17352226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylation inhibitors.
    Ardizzoni A; Loprevite M
    Suppl Tumori; 2002; 1(4):S52-4. PubMed ID: 12415821
    [No Abstract]   [Full Text] [Related]  

  • 14. Telomerase-based therapies emerging slowly.
    Brower V
    J Natl Cancer Inst; 2010 Apr; 102(8):520-1. PubMed ID: 20388877
    [No Abstract]   [Full Text] [Related]  

  • 15. Two drugs beat back lung tumors.
    Cancer Discov; 2015 Feb; 5(2):100. PubMed ID: 25656878
    [No Abstract]   [Full Text] [Related]  

  • 16. MEK/MAPK inhibitors.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S474-5. PubMed ID: 21102245
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiangiogenic agents.
    Stani SC; Capaccetti B; Bonginelli P; Sarmiento R; De Sio L; Fanelli M; Gasparini G
    Suppl Tumori; 2002; 1(4):S39-43. PubMed ID: 12415816
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents. Proceedings of the Third Cambridge Conference. September 23-24, 2005. Cambridge, Massachusetts, USA.
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4365s-4457s. PubMed ID: 16960976
    [No Abstract]   [Full Text] [Related]  

  • 19. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR.
    Simi L; Andreani M; Davini F; Janni A; Pazzagli M; Serio M; Orlando C
    Lung Cancer; 2004 Aug; 45(2):171-9. PubMed ID: 15246188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
    Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
    Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.